From the source
New Alphabet “bet” is focused on the use of artificial intelligence to accelerate drug discovery Isomorphic Labs, a subsidiary of Alphabet, today announced the first phase of its management team.
The company, established in November, was launched from Alphabet’s DeepMind to build on the success of AlphaFold, DeepMind’s work in protein folding that was heralded as the “Breakthrough of the Year” by Science and “Method of the Year” by Nature in 2021.
Isomorphic Labs’ mission is to use AI and machine learning methods to accelerate and improve the drug discovery process.
The company is a pioneer in the emerging field of “digital biology” and aims to usher in a new era of biomedical breakthroughs in order to find cures for some of humanity’s most devastating diseases.
The new leaders join founder and acting CEO Demis Hassabis, who is currently serving as CEO of both DeepMind and Isomorphic Labs.
Together they comprise a truly multidisciplinary leadership team with expertise in domains across science, engineering, machine learning and business operations that will be needed to achieve the company’s goal of dramatically improving how drugs are discovered and developed.
…
